Fideuram Asset Management Ireland dac Invests $3.82 Million in DexCom, Inc. $DXCM

Fideuram Asset Management Ireland dac bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, HoldingsChannel reports. The fund bought 57,474 shares of the medical device company’s stock, valued at approximately $3,815,000.

Several other large investors have also made changes to their positions in the company. National Pension Service boosted its stake in shares of DexCom by 10.4% in the 4th quarter. National Pension Service now owns 618,615 shares of the medical device company’s stock valued at $41,057,000 after purchasing an additional 58,262 shares during the last quarter. Inspire Trust Co. N.A. raised its position in shares of DexCom by 16.4% in the 4th quarter. Inspire Trust Co. N.A. now owns 57,039 shares of the medical device company’s stock valued at $3,786,000 after acquiring an additional 8,039 shares during the period. Rothschild Investment LLC raised its position in shares of DexCom by 62.7% in the 4th quarter. Rothschild Investment LLC now owns 1,064 shares of the medical device company’s stock valued at $71,000 after acquiring an additional 410 shares during the period. SBI Okasan Asset Management Co.Ltd. acquired a new stake in shares of DexCom in the 4th quarter valued at approximately $1,799,000. Finally, Jupiter Asset Management Ltd. raised its position in shares of DexCom by 254.7% in the 4th quarter. Jupiter Asset Management Ltd. now owns 183,265 shares of the medical device company’s stock valued at $12,163,000 after acquiring an additional 131,604 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DXCM stock opened at $72.34 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The company has a market capitalization of $27.91 billion, a P/E ratio of 30.91, a price-to-earnings-growth ratio of 1.16 and a beta of 1.40. The company’s 50 day moving average price is $64.05 and its two-hundred day moving average price is $66.39. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the company posted $0.32 EPS. On average, analysts expect that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director directly owned 25,007 shares in the company, valued at $1,500,670.07. This trade represents a 3.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $59.91, for a total transaction of $101,847.00. Following the completion of the sale, the executive vice president owned 109,504 shares in the company, valued at $6,560,384.64. This trade represents a 1.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 32,871 shares of company stock worth $2,306,638. Company insiders own 0.28% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on DXCM. William Blair upgraded shares of DexCom to a “strong-buy” rating in a research report on Friday, May 15th. Bank of America cut their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Truist Financial reiterated a “buy” rating and issued a $80.00 price target (down from $82.00) on shares of DexCom in a research report on Tuesday, February 17th. Benchmark began coverage on shares of DexCom in a research report on Monday, May 11th. They issued a “buy” rating and a $77.00 price target on the stock. Finally, Evercore upgraded shares of DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price target on the stock in a research report on Tuesday, March 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $82.42.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.